Monograph Title | Section | Source Publication Sort descending | Page Number | Errata Post Date | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
---|---|---|---|---|---|---|---|---|
ZIPRASIDONE CAPSULES | PERFORMANCE TESTS/Dissolution <711>/Test 3/Tier 2 | Revision Bulletin (Official October 01, 2019) | Online | 22-Nov-2019 | 1-Dec-2019 | NA | NA | In Buffer: Change 6.8 g/L g to: 6.8 g/L AND In Standard stock solution 2: Change Standard stock solution to: Standard stock solution 1 |
ISOSORBIDE MONONITRATE EXTENDED-RELEASE TABLETS | IMPURITIES/Organic Impurities, Procedure 1/Chromatographic system | Revision Bulletin (Official October 01, 2019) | Online | 26-Jun-2020 | 1-Jul-2020 | NA | NA | In Detection solution: Change Dissolve 1.25 g of potassium permanganate and 10.0 g of sodium hydroxide in 500 mL of water (prepared fresh for each plate), and heat at 105° for 5 min. to: Dissolve 1.25 g of potassium permanganate and 10.0 g of sodium… Read More |
OXYBUTYNIN CHLORIDE EXTENDED-RELEASE TABLETS | PERFORMANCE TESTS/Dissolution <711>/Test 2 | Revision Bulletin (Official October 01, 2019) | Online | 24-Apr-2020 | 1-May-2020 | NA | NA | In Buffer stage medium: Change Simulated gastric fluid, to: Simulated intestinal fluid, |
MINOCYCLINE HYDROCHLORIDE EXTENDED-RELEASE TABLETS | PERFORMANCE TESTS/Dissolution <711> | Revision Bulletin (Official September 01, 2019) | Online | 31-Jul-2020 | 1-Aug-2020 | NA | NA | In Test 4/Table 5: Change 45/Tablet and 90 mg/Tablet to: 45 mg/Tablet and 90 mg/Tablet |
METAXALONE TABLETS | IMPURITIES | Revision Bulletin (Official September 01, 2020) | Online | 25-Sep-2020 | 1-Oct-2020 | NA | NA | Change Organic Impurities to: IMPURITIES Organic Impurities |
NALOXONE HYDROCHLORIDE INJECTION | IMPURITIES/Limit of 2,2′-Bisnaloxone | Revision Bulletin (Official September 01, 2020) | Online | 18-Dec-2020 | 1-Jan-2021 | NA | NA | In Analysis: Change [Note—The relative retention times for naloxone and 2,2′-bisnaloxone (4,5′:4′,5″-diepoxy-3,3′,14,14′-tetrahydroxy-17,17′-bis(prop-2-enyl)-2,2′-bimorphinanyl-6,6′-dione) are 1.0 and 2.8, respectively.] to: [Note—The relative… Read More |
AZITHROMYCIN FOR INJECTION | IMPURITIES/Limit of Aminoazithromycin, Formamido Analog, Methylformamido Analog, and 3′-De(dimethylamino)-3′-oxoazithromycin | Second Supplement to USP35–NF30 | 5910 | 28-Sep-2012 | 1-Oct-2012 | USP37–NF32 | First Supplement to USP36–NF31 | Row 11 of Table 2: Change 3′-Demethyl-3′-N-[(4-methylphenyl)sulfonyl]azithromycin to: 3′-N-Demethyl-3′-N-[(4-methylphenyl)sulfonyl]azithromycin |
AZITHROMYCIN FOR INJECTION | IMPURITIES/Limit of Azithromycin N-Oxide, Desosaminylazithromycin, and N-Demethylazithromycin | Second Supplement to USP35–NF30 | 5910 | 28-Sep-2012 | 1-Oct-2012 | USP37–NF32 | First Supplement to USP36–NF31 | Line 5 of Analysis: Change Result = (rU/rS) × (CS/CU) × P × F × 100 to: Result = (rU/rS) × (CS/C… Read More |
ATRACURIUM BESYLATE INJECTION | IMPURITIES/Organic Impurities/Acceptance criteria/Table 2 | Second Supplement to USP35–NF30 | 5909 | 29-Mar-2013 | 1-Apr-2013 | USP37–NF32 | USP37–NF32 | Footnote b: Change cis isomer of the hydroxy compound. to: trans isomer of the hydroxy compound. AND Footnote c: Change trans isomer of the hydroxy compound. to: cis isomer of the hydroxy compound. AND Footnote d: Change cis… Read More |
DULOXETINE DELAYED-RELEASE CAPSULES | PERFORMANCE TESTS/Dissolution <711>/Chromatographic system | Second Supplement to USP35–NF30 | 5940 | 29-Mar-2013 | 1-Apr-2013 | USP37–NF32 | USP37–NF32 | Line 1 of Column: Change 4.6-mm x 7.5-cm; 3-µm packing L7 to: 4.6-mm x 7.5-cm; 3- or 3.5-µm packing L7 |
<232> ELEMENTAL IMPURITIES--LIMITS | Drug Products/Large Volume Parenterals | Second Supplement to USP35–NF30 | 5633 | 31-Jan-2013 | 1-Feb-2013 | USP37–NF32 | Second Supplement to USP36–NF31 | Row 16 of Column 4 of Table 1: Change 70 to: 100 AND Row 16 of Column 5 of Table 1: Change 25 to: 10 |
SUMATRIPTAN INJECTION | SPECIFIC TESTS/Osmolality and Osmolarity <785> | Second Supplement to USP35–NF30 | 5996 | 29-Mar-2013 | 1-Apr-2013 | USP37–NF32 | USP37–NF32 | Line 1: Change 270–330 mOsmol to: 270–330 mOsmol/kg |
AZITHROMYCIN FOR INJECTION | IMPURITIES/Limit of Aminoazithromycin, Formamido Analog, Methylformamido Analog, and 3’-De(dimethylamino)-3’-oxoazithromycin (if present) | Second Supplement to USP35–NF30 | 5910 | 31-Jan-2013 | 1-Feb-2013 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 1 of Buffer: Change 3.5 g/mL to: 3.5 g/L |
<232> ELEMENTAL IMPURITIES--LIMITS | Drug Substance and Excipients | Second Supplement to USP35–NF30 | 5633 | 31-Jan-2013 | 1-Feb-2013 | USP37–NF32 | Second Supplement to USP36–NF31 | Row 16 of Column 4 of Table 2: Change 7 to: 10 |
Carisoprodol Tablets | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | Second Supplement to USP35–NF30 | 5921 | 30-Nov-2012 | 1-Dec-2012 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 5: At end of USP Reference Standards, add USP Meprobamate RS |
Cefepime Hydrochloride | IMPURITIES/Organic Impurities/Procedure 1: Limit of N-Methylpyrrolidine | Second Supplement to USP35–NF30 | 5923 | 30-Nov-2012 | 1-Dec-2012 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 5 of Chromatographic system: Change Column: 4.0-mm x 25-cm; 5-µm packing L##1 to: Column: 4.0-mm x 25-cm; 5-µm packing L76 AND Delete corresponding footnote: "Available as Metrosep C4-250." |
Cefepime for Injection | IMPURITIES/Organic Impurities/Procedure 1: Limit of N-Methylpyrrolidine | Second Supplement to USP35–NF30 | 5925 | 30-Nov-2012 | 1-Dec-2012 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 5 of Chromatographic system: Change Column: 4.0-mm x 25-cm; 5-µm packing L##1 to: Column: 4.0-mm x 25-cm; 5-µm packing L76 AND Delete corresponding footnote: Available as Metrosep C4-250. |
<232> ELEMENTAL IMPURITIES—LIMITS | DRUG SUBSTANCE AND EXCIPIENTS | Second Supplement to USP35–NF30 | 5633 | 28-Sep-2012 | 1-Oct-2012 | USP37–NF32 | First Supplement to USP36–NF31 | Rows 11 and 15 of Column 2 of Table 2: Change 100 to: 10 AND Rows 11 and 15 of Column 3 of Table 2: Change 10 to: 1.0 AND Row 11 of Column 4 of Table 2: Change 1.5 to: 0.15 AND Row 15 of Column 4 of Table 2:… Read More |
<232> ELEMENTAL IMPURITIES—LIMITS | ANALYTICAL TESTING | Second Supplement to USP35–NF30 | 5633 | 28-Sep-2012 | 1-Oct-2012 | USP37–NF32 | First Supplement to USP36–NF31 | Line 6: Change Pd to: Pb |
<232> ELEMENTAL IMPURITIES—LIMITS | DRUG SUBSTANCE AND EXCIPIENTS | Second Supplement to USP35–NF30 | 5633 | 28-Sep-2012 | 1-Oct-2012 | USP37–NF32 | First Supplement to USP36–NF31 | Row 13 of Column 4 of Table 2: Change 25 to: 1.0 |
<232> ELEMENTAL IMPURITIES—LIMITS | DRUG PRODUCTS/Large Volume Parenterals | Second Supplement to USP35–NF30 | 5633 | 28-Sep-2012 | 1-Oct-2012 | USP37–NF32 | First Supplement to USP36–NF31 | Row 13 of Column 4 of Table 1: Change 250 to: 10 |
<233> ELEMENTAL IMPURITIES—PROCEDURES | INTRODUCTION/Definition | Second Supplement to USP35–NF30 | 5634 | 28-Sep-2012 | 1-Oct-2012 | USP37–NF32 | First Supplement to USP36–NF31 | Line 2 of Target Elements: Change Pd to: Pb |
LORATADINE | IMPURITIES/Organic Impurities, Procedure 1 | Second Supplement to USP36–NF31 | 6650 | 22-Nov-2013 | 1-Dec-2013 | USP38–NF33 | Second Supplement to USP37–NF32 | Line 3 of Note: Change 4,8-dichloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-one to: 4,8-dichloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-one |
PARICALCITOL INJECTION | IMPURITIES/Organic Impurities/Chromatographic system/Columns | Second Supplement to USP36–NF31 | 6678 | 22-Nov-2013 | 1-Dec-2013 | USP38–NF33 | Second Supplement to USP37–NF32 | Line 1 of Guard: Change 4.6-mm × 7.5-cm to: 4.6-mm × 7.5-mm |
RISPERIDONE ORAL SOLUTION | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | Second Supplement to USP36–NF31 | 6690 | 22-Nov-2013 | 1-Dec-2013 | USP38–NF33 | Second Supplement to USP37–NF32 | Line 2 of USP Risperidone Related Compounds Mixture RS: Change Contains a 98.9: 0.5: 0.30: 0.3 (area %) mixture of four compounds: 98.9% of Risperidone. 0.5% of Risperidone cis-N-oxide: cis-3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-… Read More |
BETHANECHOL CHLORIDE | IMPURITIES/Heavy Metals, Method 1 <231> | Second Supplement to USP36–NF31 | 6568 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Test preparation: Change Bethacholine Chloride to: Bethanechol Chloride |
TRAMADOL HYDROCHLORIDE | ASSAY/Procedure | Second Supplement to USP36–NF31 | 6715 | 22-Nov-2013 | 1-Dec-2013 | USP38–NF33 | Second Supplement to USP37–NF32 | Line 2 of System suitability solution: Change USP Tramadol Hydrochloride Related Compound A RS to: USP Tramadol Related Compound A RS |
FILGRASTIM | ASSAY/Potency | Second Supplement to USP36–NF31 | 6606 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 7 of Preparation of cells for analysis: Change Column 1 is filled with 50 L of Medium B. to: Column 1 is filled with 50 µL of Medium B. |
PANCURONIUM BROMIDE INJECTION | IMPURITIES/Organic Impurities | Second Supplement to USP36–NF31 | 6677 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Footnote a of Table 1: Change Piperidinium, 1-[(2,3,5,16,17)-17-acetyloxy-3-hydroxy-2-(1-piperidinyl)androstan-16-yl]-1-methyl bromide. to: Piperidinium, 1-[(2,3,5,16,17)-17-acetyloxy-3-hydroxy-2-(1-piperidinyl)androstan-16-yl]-1-methyl. |
BUTYLPARABEN | IMPURITIES/Related Substances/Chromatographic system | Second Supplement to USP36–NF31 | 6551 | 28-Mar-2014 | 1-Apr-2014 | USP38–NF33 | USP38–NF33 | After the Column section: Add Column temperature: 35° |
POLYMYXIN B SULFATE | IMPURITIES/Organic Impurities | Second Supplement to USP36–NF31 | 6686 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 2: Change Buffer, Mobile phase, Diluent, Sensitivity solution, to: Buffer, Mobile phase, Diluent, Standard solution, Sensitivity solution, AND Line 1 of Samples in Analysis: Change Standard solution, Sample solution, and … Read More |
CARBIDOPA AND LEVODOPA ORALLY DISINTEGRATING TABLETS | ASSAY | Second Supplement to USP36–NF31 | 6580 | 28-Mar-2014 | 1-Apr-2014 | USP38–NF33 | USP38–NF33 | Line 2 of Procedure: Change Inject the Sample solution within 2 h of preparation. Protect the volumetric solutions from light. to: Protect the volumetric solutions from light. |
ONDANSETRON INJECTION | Assay | Second Supplement to USP36–NF31 | Online | 28-Mar-2014 | 1-Apr-2014 | USP38–NF33 | USP38–NF33 | Line 7 of Procedure: Change (293.36 / 329.82)(25C / V)(rU / rS) to: (293.36 / 329.83)(25C / V)(rU / rS) AND Line 8 of Procedure: Change 329.82 to: 329.83 |
<1660> CONTAINERS GLASS-EVALUATION OF INNER SURFACE DURABILITY | EVALUATION OF THE INNER SURFACE DURABILITY/Aggressive Screening Conditions | Second Supplement to USP36–NF31 | 6221 | 31-Jan-2014 | 1-Feb-2014 | USP38–NF33 | Second Supplement to USP37–NF32 | Row 1 of Column 3 of Table 4: Change 3% Citric Acid pH 8.0 to: 3% Sodium Citrate pH 8.0 |
OIL- AND WATER-SOLUBLE VITAMINS WITH MINERALS CAPSULES | STRENGTH/Molybdenum, Method 1 | Second Supplement to USP36–NF31 | 6372 | 31-Jan-2014 | 1-Feb-2014 | USP38–NF33 | Second Supplement to USP37–NF32 | Line 2 of Standard solutions: Change 2.0 to: 5.0 |
OIL- AND WATER-SOLUBLE VITAMINS WITH MINERALS ORAL SOLUTION | STRENGTH/Chromium | Second Supplement to USP36–NF31 | 6399 | 31-Jan-2014 | 1-Feb-2014 | USP38–NF33 | Second Supplement to USP37–NF32 | Line 13 of Analysis: Change C = concentration of chromium in the Standard solution (µg/mL) to: C = concentration of chromium in the Sample solution (µg/mL) |
OIL- AND WATER-SOLUBLE VITAMINS WITH MINERALS ORAL SOLUTION | CONTAMINANTS | Second Supplement to USP36–NF31 | 6399 | 31-Jan-2014 | 1-Feb-2014 | USP38–NF33 | Second Supplement to USP37–NF32 | Add the test: Absence of Specified Microorganisms <2022>: Meet the requirements of the tests for the absence of Salmonella species, Escherichia coli, and Staphylococcus aureus |
WATER-SOLUBLE VITAMINS WITH MINERALS CAPSULES | STRENGTH/Molybdenum, Method 1 | Second Supplement to USP36–NF31 | 6479 | 31-Jan-2014 | 1-Feb-2014 | USP38–NF33 | Second Supplement to USP37–NF32 | Line 2 of Standard solutions: Change 2.0 to: 5.0 |
ISOPROPYL ALCOHOL | ASSAY/Procedure | Second Supplement to USP36–NF31 | 6638 | 31-Jan-2014 | 1-Feb-2014 | USP38–NF33 | Second Supplement to USP37–NF32 | Line 17 of Chromatographic system: Change Linear velocity: 35 cm/s to: Flow rate: 2.3 mL/min AND Row 2 of Column 1 of Table 2: Change Diethyl ether to: Ethyl ether |
BUFFER SOLUTIONS | 4. Standard Buffer Solutions/4.1 Preparation | Second Supplement to USP36–NF31 | 6244 | 22-Nov-2013 | 1-Dec-2013 | USP38–NF33 | Second Supplement to USP37–NF32 | Line 1 of 4. Boric Acid and Potassium Chloride 0.2 M: Change 12.73 g/L of boric acid to: 12.37 g/L of boric acid |
CHINESE SALVIA | COMPOSITION/Content of Salvianolic Acid B | Second Supplement to USP36–NF31 | 6331 | 22-Nov-2013 | 1-Dec-2013 | USP38–NF33 | Second Supplement to USP37–NF32 | Line 16 of Analysis: Change W = weight of Chinese Salvia used to prepare the Sample solution (mg) to: W = weight of Chinese Salvia used to prepare the Sample stock solution (mg) |
VALERIAN TINCTURE | STRENGTH/Content of Valerenic Acids | Second Supplement to USP36–NF31 | 6352 | 22-Nov-2013 | 1-Dec-2013 | USP38–NF33 | Second Supplement to USP37–NF32 | Line 1 of Acceptance criteria: Change 90.0%–120.0% to: NLT 0.015% of valerenic acids, calculated as the sum of hydroxyvalerenic acid, acetoxyvalerenic acid, and valerenic acid |
CAPSICUM OLEORESIN | SPECIFIC TESTS/Limit of Nonivamide | Second Supplement to USP36–NF31 | 6577 | 22-Nov-2013 | 1-Dec-2013 | USP38–NF33 | Second Supplement to USP37–NF32 | Line 1 of Acceptance criteria: Change on the dried basis to: on the anhydrous basis |
CYCLOBENZAPRINE HYDROCHLORIDE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | Second Supplement to USP36–NF31 | 6585 | 22-Nov-2013 | 1-Dec-2013 | USP38–NF33 | Second Supplement to USP37–NF32 | Line 2 of USP Cyclobenzaprine Related Compound A RS: Change 5-[3-(Dimethylamino)propyl]-10,11-dihydro-5H-dibenzo[a,d]-cyclohepten-5-ol. to: 5-[3-(Dimethylamino)propyl]-5H-dibenzo[a,d]-cyclohepten-5-ol. |
DIVALPROEX SODIUM EXTENDED-RELEASE TABLETS | PERFORMANCE TESTS/Dissolution <711>/Test 5 | Second Supplement to USP36–NF31 | 6592 | 22-Nov-2013 | 1-Dec-2013 | USP38–NF33 | Second Supplement to USP37–NF32 | Line 3
of Acid stage sample solution: Change suitable filter of 45-µm pore size. to: suitable filter of 0.45-µm pore size. AND Line 3 of Buffer stage sample solution: Change suitable filter of 45-µm pore size. to: suitable filter of 0.45-µm pore size. |
FERRIC AMMONIUM CITRATE | Mercury | Second Supplement to USP37–NF32 | Online | 27-Mar-2015 | 1-Apr-2015 | USP39–NF34 | USP39–NF34 | Line 1 of Procedure: Change Add 5 mL of stannous chloride solution (1 in 10) to each solution to: Add 5 mL of Stannous Chloride Solution to each solution |
GLYCERYL BEHENATE | ASSAY/Procedure/Chromatographic system | Second Supplement to USP37–NF32 | 7075 | 30-Jan-2015 | 1-Feb-2015 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 1 of Column: Change 7.0-mm × 60-cm; 5-µm packing L21 [Note—Two 7.0-mm × 30-cm L21 columns to: 7.5-mm × 60-cm; 5-µm 100-Å packing L21 [Note—Two 7.5-mm × 30-cm L21 columns |
MINERAL OIL | SPECIFIC TESTS/Readily Carbonizable Substances Test <271> | Second Supplement to USP37–NF32 | Online | 27-Mar-2015 | 1-Apr-2015 | USP39–NF34 | USP39–NF34 | Line 1 of Acceptance criteria: Change The Sample may turn hazy, but it remains colorless, or shows a slight pink or yellow color, and the Sample does not become darker than the Standard solution. to: The oil portion of the Sample may turn hazy, but it… Read More |
RISPERIDONE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | Second Supplement to USP37–NF32 | 7240 | 30-Jan-2015 | 1-Feb-2015 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 2 of USP Risperidone Related Compound G RS: Change 3-[2-[4-(4-Fluoro-2-hydroxybenzoyl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one. C23H28FN3O3 413.49 to: 3-[2-[4-(4-… Read More |
GLYCERYL BEHENATE | DEFINITION | Second Supplement to USP37–NF32 | 7077 | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 7: Change behenic (docosanic) acid to: behenic (docosanoic) acid |